MAPLE
GROVE, Minn., March 29,
2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC
(Upsher-Smith) today announced the recent launch of Methimazole
Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had
U.S. sales of approximately $36.8
million for the 12 months ending December 2023 according to IQVIA. The Therapeutic
Equivalence (TE) code for the product is AB, and the original
Reference Listed Drug (RLD) was the brand
Tapazole®*.
Product Information
Product
|
Strength
|
NDC #
|
Package
Sizes
|
Methimazole Tablets,
USP
|
5 mg
|
0832-6072-11
|
100-ct bottles / 24 per
case
|
Methimazole Tablets,
USP
|
10 mg
|
0832-6073-11
|
100-ct bottles / 24 per
case
|
For questions about ordering, please call Upsher-Smith
at 1-800-654-2299.
Please refer to the full Prescribing Information for
Methimazole Tablets, USP here. You can also call 1-888-650-3789 to
obtain a copy of the full Prescribing Information. You are
encouraged to report suspected adverse reactions to Upsher-Smith
Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting
http://www.fda.gov/medwatch.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S.
pharmaceutical company that strives to improve the health and lives
of patients through an unwavering commitment to high-quality
products and sustainable growth. The company brings generics and
brands to a wide array of customers, always backed by its attentive
level of service, strong industry relationships, and dedication to
uninterrupted supply. For more information, visit
www.upsher-smith.com.
*Tapazole is a registered trademark of King Pharmaceuticals,
Inc. As per Orange Book, Tapazole was discontinued.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/upsher-smith-launches-methimazole-tablets-usp-302103521.html
SOURCE Upsher-Smith Laboratories, LLC